Harrow (HROW) Return on Invested Capital (2017 - 2024)

Harrow's (HROW) quarterly Return on Invested Capital came in at 0.0% in Q4 2024, down 99.69% quarter-over-quarter from 0.76% in Q4 2022.

Harrow (HROW) Return on Invested Capital (2017 - 2024) Analysis & Trends

Harrow's Return on Invested Capital history runs 3 years deep, the most recent figure standing at 0.0% for Q4 2024.

On a quarterly basis, Return on Invested Capital changed N/A year-over-year to 0.0% in Q4 2024; TTM through Dec 2024 was 0.0%, a N/A change from a year earlier, with the FY2021 full-year figure at 0.76%, up 62.0% from the prior year.
Return on Invested Capital eased to 0.0% in Q4 2024 per HROW's latest filing, from 0.76% in the prior quarter.
Across five years, Return on Invested Capital topped out at 0.76% in Q4 2022 and bottomed at 0.25% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	0.01%
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	0.01%
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	0.00%
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	-
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	0.00%
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	-
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	0.03%
10	Harrow	1.56 Bn	1.47 Bn	27.05 Mn	-

Download Data